Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      COVID-19 Vaccines*/adverse effects ; COVID-19 Vaccines*/administration & dosage ; Nervous System Diseases*/epidemiology ; Nervous System Diseases*/etiology ; COVID-19*/prevention & control ; COVID-19*/epidemiology; Humans ; Female ; Male ; Case-Control Studies ; Middle Aged ; Aged ; Adult ; SARS-CoV-2/immunology ; Vaccination/adverse effects ; Stroke/epidemiology ; Stroke/prevention & control
    • Abstract:
      The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matched controls. A total of 624 participants were enrolled, and after random 1:1 matching 265 cases and 265 matched controls (total 530 participants) were included in the analyses. The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. A protective role of vaccination on the risk of developing a new neurological disorder was detected in the unadjusted analysis (OR 0.50; 95% CI 0.29-0.86; p = 0.0114). After adjustment for confounders, the number of vaccination doses received was associated with a reduced risk of developing new neurological disorders for participants aged over 60 years ( p = 0.0472; OR 0.14, 95% CI 0.03-0.68), with pre-existing comorbidities (p = 0.0122; OR 0.04, 95% CI 0.01-0.99) and for stroke (p = 0.0232; OR 0.04, 95% CI 0.02-0.97). The COVIVAX study provided no warning sign regarding an increase in the risk of developing new neurological disorders following COVID-19 vaccination of any type or doses. A potentially protective effect of multiple doses of COVID-19 vaccines against the risk of stroke in people aged over 60 needs to be confirmed by further studies.
      Competing Interests: Declarations. Competing interests: The authors declare no competing interests.
      (© 2025. The Author(s).)
    • References:
      BMJ. 2016 Sep 12;354:i4515. (PMID: 27618829)
      Neurology. 2020 Jul 14;95(2):77-84. (PMID: 32345728)
      Inflamm Res. 2020 Dec;69(12):1181-1189. (PMID: 32918567)
      J Med Virol. 2024 May;96(5):e29648. (PMID: 38727032)
      Lancet Respir Med. 2021 Dec;9(12):1439-1449. (PMID: 34599903)
      BMJ. 2020 Mar 26;368:m1091. (PMID: 32217556)
      Can J Neurol Sci. 2021 Jan;48(1):66-76. (PMID: 32665054)
      JAMA Neurol. 2020 Aug 1;77(8):1018-1027. (PMID: 32469387)
      Lancet Neurol. 2020 Sep;19(9):767-783. (PMID: 32622375)
      Lancet. 2021 May 15;397(10287):1819-1829. (PMID: 33964222)
      Int J Infect Dis. 2024 Aug;145:107080. (PMID: 38701913)
      JAMA Neurol. 2020 Jun 1;77(6):683-690. (PMID: 32275288)
      Int J Infect Dis. 2025 Feb;151:107324. (PMID: 39637971)
      Neurology. 2023 Aug 29;101(9):e892-e903. (PMID: 37414564)
      Nat Med. 2021 Dec;27(12):2144-2153. (PMID: 34697502)
      J Neurol. 2020 Jun;267(6):1573-1576. (PMID: 32436101)
      BMJ. 2022 Mar 16;376:e068373. (PMID: 35296468)
      Eur J Neurol. 2020 Sep;27(9):1712-1726. (PMID: 32503088)
      J Neurol. 2020 Aug;267(8):2179-2184. (PMID: 32458193)
      Nat Rev Neurol. 2020 Nov;16(11):636-644. (PMID: 32839585)
      Int J Public Health. 2023 Jul 07;68:1605526. (PMID: 37485047)
      J Neurol. 2021 May;268(5):1561-1569. (PMID: 32740766)
      BMJ. 2022 Mar 16;376:o522. (PMID: 35296459)
      Neurology. 2020 Aug 25;95(8):e1060-e1070. (PMID: 32482845)
      Epilepsia. 2021 Oct;62(10):2395-2404. (PMID: 34309011)
      Lancet Neurol. 2020 Nov;19(11):919-929. (PMID: 33031735)
    • Contributed Indexing:
      Keywords: Attributable risk; COVID-19; Case-control study; Epidemiology; Neurological disorders; Vaccines
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20250205 Date Completed: 20250205 Latest Revision: 20250207
    • Publication Date:
      20250207
    • Accession Number:
      PMC11794632
    • Accession Number:
      10.1038/s41598-025-88837-0
    • Accession Number:
      39905221